Goldilocks Therapeutics is structured around development of preventatives treatments for acute kidney injury, polycystic kidney disease, and other kidney conditions. The company uses its proprietary mesoscale nanoparticles (MNPs) specifically to target therapeutic payloads to the renal tubule epithelium. Drugs are under development that are intended to treat acute kidney injury and polycystic kidney diseases - specifically targeting therapeutic payloads to the renal tubule epithelium and delivery of therapeutic payloads in a sustained-release manner to patients, enabling healthcare providers to treat their patients and improve their lives.
